M. E. Scheulen

7.2k total citations · 1 hit paper
178 papers, 5.5k citations indexed

About

M. E. Scheulen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. E. Scheulen has authored 178 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 55 papers in Molecular Biology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. E. Scheulen's work include Cancer Treatment and Pharmacology (38 papers), Colorectal Cancer Treatments and Studies (24 papers) and Cancer therapeutics and mechanisms (17 papers). M. E. Scheulen is often cited by papers focused on Cancer Treatment and Pharmacology (38 papers), Colorectal Cancer Treatments and Studies (24 papers) and Cancer therapeutics and mechanisms (17 papers). M. E. Scheulen collaborates with scholars based in Germany, United States and Switzerland. M. E. Scheulen's co-authors include Dirk Strumberg, Ralf A. Hilger, S. Seeber, Heike Richly, H. Kappus, D. Voliotis, K. Mross, Brian Schwartz, E. Brendel and R. Voigtmann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

M. E. Scheulen

174 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

2004 694 citations Dirk Strumberg, Heike Richly et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. E. Scheulen Germany	36	2.6k	2.3k	1.2k	734	612	178	5.5k
Robert Justice United States	40	2.5k 1.0×	2.8k 1.2×	1.7k 1.5×	871 1.2×	558 0.9×	61	6.4k
Youcef M. Rustum United States	51	3.7k 1.4×	3.5k 1.6×	1.3k 1.1×	1.1k 1.5×	726 1.2×	246	8.2k
K. Mross Germany	37	3.1k 1.2×	2.1k 0.9×	1.0k 0.9×	606 0.8×	361 0.6×	148	5.2k
Alexander Laird United States	32	1.7k 0.6×	2.7k 1.2×	1.2k 1.1×	745 1.0×	603 1.0×	97	4.9k
Jean‐Pierre Armand France	42	3.7k 1.4×	2.6k 1.1×	2.1k 1.8×	827 1.1×	515 0.8×	161	6.9k
Ferry A.L.M. Eskens Netherlands	43	2.9k 1.1×	2.6k 1.1×	1.5k 1.3×	1.2k 1.7×	601 1.0×	161	6.4k
Dirk Strumberg Germany	42	3.1k 1.2×	3.5k 1.6×	1.6k 1.4×	1.2k 1.6×	727 1.2×	141	7.4k
S. Gail Eckhardt United States	36	2.5k 1.0×	2.6k 1.2×	1.1k 1.0×	1.2k 1.6×	489 0.8×	105	5.3k
Raymond J. Hohl United States	40	1.5k 0.6×	2.3k 1.0×	624 0.5×	818 1.1×	366 0.6×	138	4.9k
Jean L. Grem United States	41	3.0k 1.2×	1.8k 0.8×	970 0.8×	539 0.7×	580 0.9×	168	5.9k

Countries citing papers authored by M. E. Scheulen

Since Specialization

Citations

This map shows the geographic impact of M. E. Scheulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Scheulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Scheulen more than expected).

Fields of papers citing papers by M. E. Scheulen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Scheulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Scheulen. The network helps show where M. E. Scheulen may publish in the future.

Co-authorship network of co-authors of M. E. Scheulen

This figure shows the co-authorship network connecting the top 25 collaborators of M. E. Scheulen. A scholar is included among the top collaborators of M. E. Scheulen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. E. Scheulen. M. E. Scheulen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bodoky, G., M. E. Scheulen, Fernando Rivera, et al.. (2015). Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer. 46(2). 109–117. 15 indexed citations

Bauer, Sebastian, Thomas Mühlenberg, Florian Grabellus, et al.. (2014). Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer. 110(5). 1155–1162. 39 indexed citations

Infante, Jeffrey R., Bradley G. Somer, Joon Oh Park, et al.. (2014). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer. 50(12). 2072–2081. 271 indexed citations

Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations

Mross, K., Heike Richly, Richard Fischer, et al.. (2013). First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors. PLoS ONE. 8(12). e83232–e83232. 41 indexed citations

Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations

Raoul, Jean‐Luc, Jordi Bruix, Tim F. Greten, et al.. (2012). Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology. 56(5). 1080–1088. 102 indexed citations

Heusner, Till A., et al.. (2011). Transarterial Hepatic Chemoperfusion of Uveal Melanoma Metastases: Survival and Response to Treatment. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 183(12). 1151–1160. 20 indexed citations

Schultheis, Beate, Dirk Strumberg, Lothar Bergmann, et al.. (2011). Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Investigational New Drugs. 30(3). 1184–1192. 12 indexed citations

10.

Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2011). Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.. Journal of Clinical Oncology. 29(15_suppl). 3017–3017. 7 indexed citations

11.

Schmidt, Marcus, M. E. Scheulen, Christian Dittrich, et al.. (2009). An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. 21(2). 275–282. 108 indexed citations

12.

Scheulen, M. E., et al.. (2006). Bortezomib. DMW - Deutsche Medizinische Wochenschrift. 131(5). 214–218. 1 indexed citations

13.

Schmittel, Alexander, M. E. Scheulen, Nikolaos E. Bechrakis, et al.. (2005). Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Research. 15(3). 205–207. 40 indexed citations

14.

Strumberg, Dirk, Heiner Boeing, M. E. Scheulen, H Förster, & S. Seeber. (2004). Ernährung, Lifestyle und Krebs: Wege zur Primärprävention. DMW - Deutsche Medizinische Wochenschrift. 129(36). 1877–1882. 1 indexed citations

15.

Beelen, Dietrich W., Rudolf Trenschel, J. Casper, et al.. (2004). Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplantation. 35(3). 233–241. 84 indexed citations

16.

Bojko, Peter, Anja Welt, Regina Schleucher, et al.. (2004). High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplantation. 34(7). 637–643. 10 indexed citations

17.

Kasimir‐Bauer, Sabine, Dietrich W. Beelen, Michael Flaßhove, et al.. (2002). Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Experimental Hematology. 30(11). 1302–1308. 29 indexed citations

18.

Harstrick, A., Hans‐Joachim Wilke, Wilfried Eberhardt, et al.. (1996). A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer. Oncology Research and Treatment. 19(2). 153–156. 20 indexed citations

19.

Becher, R., O. Kloke, Dieter May, et al.. (1991). Ifosfamide. Methotrexate and 5-Fluorouracil for Pretreated Advanced Breast Cancer. Oncology. 48(6). 459–463. 2 indexed citations

20.

Wollenberg, Peter, et al.. (1976). [Effect of 2-hydroxyestradiol-17beta on NADPH-dependent electron transfer in rat liver microsomes in vitro (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 357(3). 351–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact